Skip to main content
Erschienen in: International Journal of Hematology 6/2017

04.02.2017 | Original Article

The fibrous form of intracellular inclusion bodies in recombinant variant fibrinogen-producing cells is specific to the hepatic fibrinogen storage disease-inducible variant fibrinogen

verfasst von: Shinpei Arai, Naoko Ogiwara, Saki Mukai, Yuka Takezawa, Mitsutoshi Sugano, Takayuki Honda, Nobuo Okumura

Erschienen in: International Journal of Hematology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Fibrinogen storage disease (FSD) is a rare disorder that is characterized by the accumulation of fibrinogen in hepatocytes and induces liver injury. Six mutations in the γC domain (γG284R, γT314P, γD316N, the deletion of γG346-Q350, γG366S, and γR375W) have been identified for FSD. Our group previously established γ375W fibrinogen-producing Chinese hamster ovary (CHO) cells and observed aberrant large granular and fibrous forms of intracellular inclusion bodies. The aim of this study was to investigate whether fibrous intracellular inclusion bodies are specific to FSD-inducible variant fibrinogen. Thirteen expression vectors encoding the variant γ-chain were stably or transiently transfected into CHO cells expressing normal fibrinogen Aα- and Bβ-chains or HuH-7 cells, which were then immunofluorescently stained. Six CHO and HuH-7 cell lines that transiently produced FSD-inducible variant fibrinogen presented the fibrous (3.2–22.7 and 2.1–24.5%, respectively) and large granular (5.4–25.5 and 7.7–23.9%) forms of intracellular inclusion bodies. Seven CHO and HuH-7 cell lines that transiently produced FSD-non-inducible variant fibrinogen only exhibit the large granular form. These results demonstrate that transiently transfected variant fibrinogen-producing CHO cells and inclusion bodies of the fibrous form may be useful in non-invasive screening for FSD risk factors for FSD before its onset.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894–904.CrossRefPubMed Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894–904.CrossRefPubMed
2.
Zurück zum Zitat Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol. 2007;14:236–41.CrossRefPubMed Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol. 2007;14:236–41.CrossRefPubMed
3.
Zurück zum Zitat De Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35:56–66.CrossRef De Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35:56–66.CrossRef
4.
Zurück zum Zitat Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen Brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a γ284 Gly→Arg mutation. Am J Pathol. 2000;157:189–96.CrossRefPubMedPubMedCentral Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen Brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a γ284 Gly→Arg mutation. Am J Pathol. 2000;157:189–96.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Puls F, Goldschmidt I, Bantel H, Agne C, Bröcker V, Dämmrich M, et al. Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease. J Hepatol. 2013;59:626–30.CrossRefPubMed Puls F, Goldschmidt I, Bantel H, Agne C, Bröcker V, Dämmrich M, et al. Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease. J Hepatol. 2013;59:626–30.CrossRefPubMed
6.
Zurück zum Zitat Brennan SO, Davis RL, Conard K, Savo A, Furuya KN. Novel fibrinogen mutation γ314Thr→Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int. 2010;30:1541–7.CrossRefPubMed Brennan SO, Davis RL, Conard K, Savo A, Furuya KN. Novel fibrinogen mutation γ314Thr→Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int. 2010;30:1541–7.CrossRefPubMed
7.
Zurück zum Zitat Dib N, Quelin F, Ternisien C, Hanss M, Michalak S, De Mazancourt P, et al. Fibrinogen angers with a new deletion (γGVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost. 2007;5:1999–2005.CrossRefPubMed Dib N, Quelin F, Ternisien C, Hanss M, Michalak S, De Mazancourt P, et al. Fibrinogen angers with a new deletion (γGVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost. 2007;5:1999–2005.CrossRefPubMed
8.
Zurück zum Zitat Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM. Novel fibrinogen γ375 Arg→Trp mutation (fibrinogen Aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology. 2002;36:652–8.CrossRefPubMed Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM. Novel fibrinogen γ375 Arg→Trp mutation (fibrinogen Aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology. 2002;36:652–8.CrossRefPubMed
9.
Zurück zum Zitat Francalanci P, Santorelli FM, Talini I, Boldrini R, Devito R, Camassei FD, et al. Severe liver disease in early childhood due to fibrinogen storage and de novo gamma375Arg→Trp gene mutation. J Pediatr. 2006;148:396–8.CrossRefPubMed Francalanci P, Santorelli FM, Talini I, Boldrini R, Devito R, Camassei FD, et al. Severe liver disease in early childhood due to fibrinogen storage and de novo gamma375Arg→Trp gene mutation. J Pediatr. 2006;148:396–8.CrossRefPubMed
10.
Zurück zum Zitat Rubbia-Brandt L, Neerman-Arbez M, Rougemont A-L, Malé P-J, Spahr L. Fibrinogen gamma375 Arg→Trp mutation (fibrinogen Aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol. 2006;30:906–11.CrossRefPubMed Rubbia-Brandt L, Neerman-Arbez M, Rougemont A-L, Malé P-J, Spahr L. Fibrinogen gamma375 Arg→Trp mutation (fibrinogen Aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol. 2006;30:906–11.CrossRefPubMed
11.
Zurück zum Zitat Sogo T, Nagasaka H, Komatsu H, Inui A, Miida T, Callea F, et al. Fibrinogen storage disease caused by Aguadilla mutation presenting with hypobeta-lipoproteinemia and considerable liver disease. J Pediatr Gastroenterol Nutr. 2009;49:133–6.CrossRefPubMed Sogo T, Nagasaka H, Komatsu H, Inui A, Miida T, Callea F, et al. Fibrinogen storage disease caused by Aguadilla mutation presenting with hypobeta-lipoproteinemia and considerable liver disease. J Pediatr Gastroenterol Nutr. 2009;49:133–6.CrossRefPubMed
12.
Zurück zum Zitat Al-Hussaini A, Altalhi A, El Hag I, Al-Hussaini H, Francalanci P, Giovannoni I, et al. Hepatic fibrinogen storage disease due to the fibrinogen γ375 Arg→Trp mutation “fibrinogen Aguadilla” is present in Arabs. Saudi J Gastroenterol. 2014;20:255–61.CrossRefPubMedPubMedCentral Al-Hussaini A, Altalhi A, El Hag I, Al-Hussaini H, Francalanci P, Giovannoni I, et al. Hepatic fibrinogen storage disease due to the fibrinogen γ375 Arg→Trp mutation “fibrinogen Aguadilla” is present in Arabs. Saudi J Gastroenterol. 2014;20:255–61.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Casini A, Sokollik C, Lukowski SW, Lurz E, Rieubland C, de Moerloose P, et al. Hypofibrinogenemia and liver disease: a new case of Aguadilla fibrinogen and review of the literature. Haemophilia. 2015;21:820–7.CrossRefPubMed Casini A, Sokollik C, Lukowski SW, Lurz E, Rieubland C, de Moerloose P, et al. Hypofibrinogenemia and liver disease: a new case of Aguadilla fibrinogen and review of the literature. Haemophilia. 2015;21:820–7.CrossRefPubMed
14.
Zurück zum Zitat Sari S, Yilmaz G, Gonul II, Dalgic B, Akyol G, Giovannoni I, et al. Fibrinogen storage disease and cirrhosis associated with hypobetalipoproteinemia owing to fibrinogen Aguadilla in a Turkish child. Liver Int. 2015;35:2501–5.CrossRefPubMed Sari S, Yilmaz G, Gonul II, Dalgic B, Akyol G, Giovannoni I, et al. Fibrinogen storage disease and cirrhosis associated with hypobetalipoproteinemia owing to fibrinogen Aguadilla in a Turkish child. Liver Int. 2015;35:2501–5.CrossRefPubMed
15.
Zurück zum Zitat Asselta R, Robusto M, Braidotti P, Peyvandi F, Nastasio S, D’Antiga L, et al. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on fibrinogen γ-module. J Thromb Haemost. 2015;13:1459–67.CrossRefPubMed Asselta R, Robusto M, Braidotti P, Peyvandi F, Nastasio S, D’Antiga L, et al. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on fibrinogen γ-module. J Thromb Haemost. 2015;13:1459–67.CrossRefPubMed
16.
Zurück zum Zitat Carrell RW, Lomas DA. Alpha 1-antitrypsin deficiency—a model for conformational diseases. N Engl J Med. 2002;346:45–53.CrossRefPubMed Carrell RW, Lomas DA. Alpha 1-antitrypsin deficiency—a model for conformational diseases. N Engl J Med. 2002;346:45–53.CrossRefPubMed
17.
Zurück zum Zitat Lawless MW, Greene CM, Mulgrew A, Taggart CC, O’Neill SJ, McElvaney NG. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol. 2004;17:5722–6.CrossRef Lawless MW, Greene CM, Mulgrew A, Taggart CC, O’Neill SJ, McElvaney NG. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol. 2004;17:5722–6.CrossRef
18.
Zurück zum Zitat Teckman JH, An J-K, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol. 2004;286:G851–62.CrossRefPubMed Teckman JH, An J-K, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol. 2004;286:G851–62.CrossRefPubMed
19.
Zurück zum Zitat Kobayashi T, Arai S, Ogiwara N, Takezawa Y, Nanya M, Terasawa F, et al. γ375W fibrinogen-synthesizing CHO cells indicate the accumulation of variant fibrinogen within endoplasmic reticulum. Thromb Res. 2014;133:101–7.CrossRefPubMed Kobayashi T, Arai S, Ogiwara N, Takezawa Y, Nanya M, Terasawa F, et al. γ375W fibrinogen-synthesizing CHO cells indicate the accumulation of variant fibrinogen within endoplasmic reticulum. Thromb Res. 2014;133:101–7.CrossRefPubMed
20.
Zurück zum Zitat Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation: clot retraction does not require an intact fibrinogen chain C terminus. J Biol Chem. 1996;271:8553–5.CrossRefPubMed Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation: clot retraction does not require an intact fibrinogen chain C terminus. J Biol Chem. 1996;271:8553–5.CrossRefPubMed
21.
Zurück zum Zitat Haneishi A, Terasawa F, Fujihara N, Yamauchi K, Okumura N, Katsuyama T. Recombinant variant fibrinogens substituted at residues γ326Cys and γ339Cys demonstrated markedly impaired secretion of assembled fibrinogen. Thromb Res. 2009;124:368–72.CrossRefPubMed Haneishi A, Terasawa F, Fujihara N, Yamauchi K, Okumura N, Katsuyama T. Recombinant variant fibrinogens substituted at residues γ326Cys and γ339Cys demonstrated markedly impaired secretion of assembled fibrinogen. Thromb Res. 2009;124:368–72.CrossRefPubMed
22.
Zurück zum Zitat Terasawa F, Kamijyo Y, Fujihara N, Okumura N. Assembly and secretion of mutant fibrinogens with variant gamma-chain C terminal region (γ313-γ345). Rinsho Byori. 2010;58:772–8 (in Japanese).PubMed Terasawa F, Kamijyo Y, Fujihara N, Okumura N. Assembly and secretion of mutant fibrinogens with variant gamma-chain C terminal region (γ313-γ345). Rinsho Byori. 2010;58:772–8 (in Japanese).PubMed
23.
Zurück zum Zitat Okumura N, Gorkun OV, Lord ST. Severely impaired polymerization of recombinant fibrinogen γ364 Asp→His, the substitution discovered in a heterozygous individual. J Biol Chem. 1997;272:29596–601.CrossRefPubMed Okumura N, Gorkun OV, Lord ST. Severely impaired polymerization of recombinant fibrinogen γ364 Asp→His, the substitution discovered in a heterozygous individual. J Biol Chem. 1997;272:29596–601.CrossRefPubMed
24.
Zurück zum Zitat Terasawa F, Okumura N, Kitano K, Hayashida N, Shimosaka M, Okazaki M, et al. Hypofibrinogenemia associated with a heterozygous missense mutation γ153Cys to Arg (Matsumoto IV): in vitro expression demonstrates defective secretion of the variant fibrinogen. Blood. 1999;94:4122–31.PubMed Terasawa F, Okumura N, Kitano K, Hayashida N, Shimosaka M, Okazaki M, et al. Hypofibrinogenemia associated with a heterozygous missense mutation γ153Cys to Arg (Matsumoto IV): in vitro expression demonstrates defective secretion of the variant fibrinogen. Blood. 1999;94:4122–31.PubMed
25.
Zurück zum Zitat Okumura N, Terasawa F, Tanaka H, Hirota M, Ota H, Kitano K, et al. Analysis of fibrinogen γ-chain truncations shows the C-terminus, particularly γIle387, is essential for assembly and secretion of this multichain protein. Blood. 2002;99:3654–60.CrossRefPubMed Okumura N, Terasawa F, Tanaka H, Hirota M, Ota H, Kitano K, et al. Analysis of fibrinogen γ-chain truncations shows the C-terminus, particularly γIle387, is essential for assembly and secretion of this multichain protein. Blood. 2002;99:3654–60.CrossRefPubMed
26.
Zurück zum Zitat Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42:3858–63.PubMed Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42:3858–63.PubMed
27.
Zurück zum Zitat Meyer M, Bergmann F, Brennan SO. Novel fibrinogen mutation (γ313 Ser→Asn) associated with hypofibrinogenemia in two unrelated families. Blood Coagul Fibrinolysis. 2006;17:63–7.CrossRefPubMed Meyer M, Bergmann F, Brennan SO. Novel fibrinogen mutation (γ313 Ser→Asn) associated with hypofibrinogenemia in two unrelated families. Blood Coagul Fibrinolysis. 2006;17:63–7.CrossRefPubMed
28.
Zurück zum Zitat Guglielmone HA, Sanchez MC, Abate Daga D, Bocco JL. A new heterozygous mutation in gamma fibrinogen gene leading to 326 Cys→Ser substitution in fibrinogen Córdoba is associated with defective polymerization and familial hypodysfibrinogenemia. J Thromb Haemost. 2004;2:352–4.CrossRefPubMed Guglielmone HA, Sanchez MC, Abate Daga D, Bocco JL. A new heterozygous mutation in gamma fibrinogen gene leading to 326 Cys→Ser substitution in fibrinogen Córdoba is associated with defective polymerization and familial hypodysfibrinogenemia. J Thromb Haemost. 2004;2:352–4.CrossRefPubMed
29.
Zurück zum Zitat Dear A, Brennan SO, George PM. Familial hypodysfibrinogenaemia associated with second occurrence of γ326 Cys→Tyr mutation. Thromb Haemost. 2005;93:612–3.PubMed Dear A, Brennan SO, George PM. Familial hypodysfibrinogenaemia associated with second occurrence of γ326 Cys→Tyr mutation. Thromb Haemost. 2005;93:612–3.PubMed
30.
Zurück zum Zitat Meyer M, Franke K, Richter W, Steiniger F, Seyfert UT, Schenk J, et al. New molecular defects in the gamma subdomain of fibrinogen D-domain in four cases of (hypo)dysfibrinogenemia: fibrinogen variants Hannover VI, Homburg VII, Stuttgart and Suhl. Thromb Haemost. 2003;89:637–46.PubMed Meyer M, Franke K, Richter W, Steiniger F, Seyfert UT, Schenk J, et al. New molecular defects in the gamma subdomain of fibrinogen D-domain in four cases of (hypo)dysfibrinogenemia: fibrinogen variants Hannover VI, Homburg VII, Stuttgart and Suhl. Thromb Haemost. 2003;89:637–46.PubMed
31.
Zurück zum Zitat Song KS, Park NJ, Choi JR, Doh HJ, Chung KH. Fibrinogen Seoul (FGG Ala341Asp): a novel mutation associated with hypodysfibrinogenemia. Clin Appl Thromb Hemost. 2006;12:338–43.CrossRefPubMed Song KS, Park NJ, Choi JR, Doh HJ, Chung KH. Fibrinogen Seoul (FGG Ala341Asp): a novel mutation associated with hypodysfibrinogenemia. Clin Appl Thromb Hemost. 2006;12:338–43.CrossRefPubMed
Metadaten
Titel
The fibrous form of intracellular inclusion bodies in recombinant variant fibrinogen-producing cells is specific to the hepatic fibrinogen storage disease-inducible variant fibrinogen
verfasst von
Shinpei Arai
Naoko Ogiwara
Saki Mukai
Yuka Takezawa
Mitsutoshi Sugano
Takayuki Honda
Nobuo Okumura
Publikationsdatum
04.02.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2185-5

Weitere Artikel der Ausgabe 6/2017

International Journal of Hematology 6/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.